UNIGE document Scientific Article
previous document  unige:55627  next document
add to browser collection
Title

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Authors
Koeberle, D
Betticher, D C
von Moos, R
Dietrich, D
Brauchli, P
Baertschi, D
Matter, K
Winterhalder, R
show hidden authors show all authors [1 - 20]
Published in Annals of Oncology. 2015, vol. 26, no. 4, p. 709-14
Abstract Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after completing first-line chemotherapy.
Identifiers
PMID: 25605741
Full text
Article (Published version) (184 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Groupe Roth Arnaud (oncologie) (285)
Citation
(ISO format)
KOEBERLE, D et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). In: Annals of Oncology, 2015, vol. 26, n° 4, p. 709-14. https://archive-ouverte.unige.ch/unige:55627

195 hits

1 download

Update

Deposited on : 2015-04-20

Export document
Format :
Citation style :